Hội nghị công bố kết quả kinh doanh quý 3 năm 2026 của Fulgent Genetics (FLGT): Doanh thu tăng 8%, lỗ thu hẹp
Doanh thu quý 3/2026 của Fulgent Genetics tăng 8% lên 90,4 triệu USD trong bối cảnh khoản lỗ thu hẹp, hoạt động thu hồi công nợ được cải thiện và định hướng cả năm được tái khẳng định.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.